Stock 8225 CHINA HEALTH GROUP INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials China Health Group Inc.

Equities

8225

KYG2117N1088

Biotechnology & Medical Research

Delayed Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
0.119 HKD -0.83% Intraday chart for China Health Group Inc. +9.17% -13.77%
Mar. 26 China Health Group Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 12 China Health Group Inc. Announces Directorate Changes CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 197.6 157.8 91.38 343.5 312.2 254.9
Enterprise Value (EV) 1 191.4 150.3 87.04 316.6 295.2 242.9
P/E ratio 6.49 x 6.81 x 3.29 x 5.68 x 8.6 x -16.1 x
Yield - - - - - -
Capitalization / Revenue 3.38 x 2.65 x 1.45 x 4.14 x 3.73 x 19.5 x
EV / Revenue 3.27 x 2.52 x 1.38 x 3.81 x 3.53 x 18.6 x
EV / EBITDA 5.47 x 5.23 x 2.58 x 5.72 x 6.98 x -15.3 x
EV / FCF 37.9 x -32.3 x -11 x -42 x -14.9 x 284 x
FCF Yield 2.64% -3.1% -9.12% -2.38% -6.73% 0.35%
Price to Book 34.1 x 5.41 x 1.6 x 2.89 x 2.01 x 1.79 x
Nbr of stocks (in thousands) 992,772 992,772 992,772 995,352 995,352 995,352
Reference price 2 0.1991 0.1589 0.0920 0.3451 0.3137 0.2561
Announcement Date 4/2/18 6/9/19 3/30/20 3/30/21 3/31/22 4/14/23
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 58.49 59.61 63.22 83.06 83.6 13.09
EBITDA 1 34.99 28.73 33.75 55.32 42.29 -15.86
EBIT 1 33.97 27.69 32.62 55.14 42.09 -16.01
Operating Margin 58.07% 46.45% 51.6% 66.38% 50.34% -122.31%
Earnings before Tax (EBT) 1 33.9 27.67 32.45 70.8 42.52 -15.83
Net income 1 30.45 23.16 27.79 60.65 36.32 -15.83
Net margin 52.07% 38.86% 43.96% 73.02% 43.45% -120.9%
EPS 2 0.0307 0.0233 0.0280 0.0608 0.0365 -0.0159
Free Cash Flow 1 5.053 -4.654 -7.94 -7.547 -19.86 0.8545
FCF margin 8.64% -7.81% -12.56% -9.09% -23.75% 6.53%
FCF Conversion (EBITDA) 14.44% - - - - -
FCF Conversion (Net income) 16.59% - - - - -
Dividend per Share - - - - - -
Announcement Date 4/2/18 6/9/19 3/30/20 3/30/21 3/31/22 4/14/23
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 6.26 7.5 4.34 26.9 17 12.1
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 5.05 -4.65 -7.94 -7.55 -19.9 0.85
ROE (net income / shareholders' equity) -315% 132% 64.5% 69.1% 26.5% -10.6%
ROA (Net income/ Total Assets) 93.2% 34.1% 22.6% 25.4% 14.7% -5.37%
Assets 1 32.69 67.95 122.7 238.6 247.2 294.9
Book Value Per Share 2 0.0100 0.0300 0.0600 0.1200 0.1600 0.1400
Cash Flow per Share 2 0.0100 0.0100 0.0100 0.0200 0.0100 0
Capex - 1.59 0 - - -
Capex / Sales - 2.67% 0% - - -
Announcement Date 4/2/18 6/9/19 3/30/20 3/30/21 3/31/22 4/14/23
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CHINA HEALTH GROUP INC. Stock China Health Group Inc.
-13.77% 15.13M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 8225 Stock
  4. Financials China Health Group Inc.